|Bid||0.00 x 900|
|Ask||125.00 x 800|
|Day's Range||106.33 - 111.46|
|52 Week Range||35.25 - 111.46|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||118.67|
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or recurrent cancer. The Oncotype MAP test, previously known as PCDx, provides clinically actionable information from genomic alterations in hundreds of cancer-related genes, allowing physicians to understand a patient's tumor profile and effectively recommend targeted therapies or clinical trials.